hotspot -WSS

hotspot

author：knowledge 2025-10-01 18:34:34 - browse：743

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Histogen: Failed biotech offers rare public look inside

focus

WSS

Listen: BridgeBio's big week & Lilly's Alzheimer's data

A virus, fished out of a lake, may have saved a man’s life

Sana to lay off nearly a third of staff, de

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

AI can decode, harness the power of the humane immune system

hotspot

hotspot

Wikipedia

How one medical school became remarkably diverse

FDA rejects Alnylam's heart disease treatment over insufficient data

In age of alternative facts, a scholarly course on calling out crap

'The View' co

Affirmative action in medical school literally saved lives

Senate panel eyes new effort on drug shortages

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why the advice to take all your antibiotics may be wrong

As demand for Covid shots wanes, Moderna seeks its next success

Senate panel eyes new effort on drug shortages

focus

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Bristol 'take

A new deal aims to ramp up use of AI in rehab care decisions

Was Amgen transparent enough on FDA's concern on cancer drug?

Sana to lay off nearly a third of staff, de

A Q&A with the global head of Boehringer Ingelheim's innovation unit

focus

explore

focus

entertainment